Abstract A034: KRAS Mutation-Specific effects on the Tumor Immune Microenvironment Drive Tumor Progression

Abstract The immune microenvironment plays a critical role in cancer development, progression and resistance to therapy. KRAS mutations are near-ubiquitous in pancreatic ductal adenocarcinoma (PDAC) and several studies have demonstrated that KRASG12D can create an immunosuppressive tumor microenvironment. However, the immune effects of other oncogenic KRAS variants, such as KRASG12R (representing 20% of PDAC cases) are unknown. Given that specific KRAS mutants display distinct molecular phenotypes, we examined the immune cell composition of KRASG12R pancreatic tumors. Orthotopically implanted mouse tumors derived from KrasG12R/+;Trp53KO pancreatic organoids have a distinct immune profile in comparison to KrasG12D/+;Trp53KO tumors, characterized by an influx of intratumoral CD4+ T cells and mature dendritic cells. RNA sequencing of KRASG12R tumor cells revealed enrichment of Type I interferon (IFN) pathways accompanied by related chemokines, CXCL9 and CXCL10 in comparison to KRASG12D tumors. Analysis of publicly available human PDAC cohorts revealed enrichment of genes in inflammatory pathways in KRASG12R tumors. Collectively, these data link KRASG12R to a unique immune landscape that is distinct from KRASG12D tumors. Citation Format: Andrew wenger, Tal Baron, Erika Hissong, Adrian Vega-Perez, Whitney Sisso, Maria Paz Zafra, Rohit Chandwani, Lukas Dow, Despina Siolas. KRAS Mutation-Specific effects on the Tumor Immune Microenvironment Drive Tumor Progression [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research; 2024 Sep 15-18; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl_2):Abstract nr A034.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2024-09-15
DOI
https://doi.org/10.1158/1538-7445.pancreatic24-a034
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract A034: KRAS Mutation-Specific effects on the Tumor Immune Microenvironment Drive Tumor Progression

Whitney J. Sisso, Despina Siolas, María Paz Zafra, Lukas E. Dow et al.
Cancer Research
Cancer Immunotherapy and Biomarkers
article

Abstract A034: KRAS Mutation-Specific effects on the Tumor Immune Microenvironment Drive Tumor Progression

Whitney J. Sisso, Despina Siolas, María Paz Zafra, Lukas E. Dow, Erika Hissong, Rohit Chandwani, Adrián Vega‐Pérez, Andrew Wenger, Tal Baron
article en

Abstract

Abstract The immune microenvironment plays a critical role in cancer development, progression and resistance to therapy. KRAS mutations are near-ubiquitous in pancreatic ductal adenocarcinoma (PDAC) and several studies have demonstrated that KRASG12D can create an immunosuppressive tumor microenvironment. However, the immune effects of other oncogenic KRAS variants, such as KRASG12R (representing 20% of PDAC cases) are unknown. Given that specific KRAS mutants display distinct molecular phenotypes, we examined the immune cell composition of KRASG12R pancreatic tumors. Orthotopically implanted mouse tumors derived from KrasG12R/+;Trp53KO pancreatic organoids have a distinct immune profile in comparison to KrasG12D/+;Trp53KO tumors, characterized by an influx of intratumoral CD4+ T cells and mature dendritic cells. RNA sequencing of KRASG12R tumor cells revealed enrichment of Type I interferon (IFN) pathways accompanied by related chemokines, CXCL9 and CXCL10 in comparison to KRASG12D tumors. Analysis of publicly available human PDAC cohorts revealed enrichment of genes in inflammatory pathways in KRASG12R tumors. Collectively, these data link KRASG12R to a unique immune landscape that is distinct from KRASG12D tumors. Citation Format: Andrew wenger, Tal Baron, Erika Hissong, Adrian Vega-Perez, Whitney Sisso, Maria Paz Zafra, Rohit Chandwani, Lukas Dow, Despina Siolas. KRAS Mutation-Specific effects on the Tumor Immune Microenvironment Drive Tumor Progression [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research; 2024 Sep 15-18; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl_2):Abstract nr A034.

Cancer ResearchVol. 84(17_Supplement_2)
Exploratorium (US), Universidad de Granada (ES), Cornell University (US), Weill Cornell Medicine (US)
Good health and well-being
Openalex Percentile: Top 74%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.